Evidence for a novel binding site conformer of aldose reductase in ligand-bound state

被引:32
作者
Steuber, Holger
Zentgraf, Matthias
La Motta, Concettina
Sartini, Stefania
Heine, Andreas
Klebe, Gerhard
机构
[1] Univ Marburg, Dept Pharmaceut Chem, D-35032 Marburg, Germany
[2] Univ Pisa, Dipartimento Sci Farmaceut, I-56126 Pisa, Italy
关键词
protein flexibility; aldose reductase; binding site; structure-based drug design; induced-fit interaction;
D O I
10.1016/j.jmb.2007.03.021
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human aldose reductase (ALR2) has evolved as a promising therapeutic target for the treatment of diabetic long-term complications. The binding site of this enzyme possesses two main subpockets: the catalytic anion-binding site and the hydrophobic specificity pocket. The latter can be observed in the open or closed state, depending on the bound ligand. Thus, it exhibits a pronounced capability for induced-fit adaptations, whereas the, catalytic pocket exhibits rigid properties throughout all known crystal, structures. Here, we determined two ALR2 crystal structures at 1.55 and 1.65 angstrom resolution, each complexed with an inhibitor of the recently described naphtho[1,2-d]isothiazole acetic acid series. In contrast to the original design hypothesis based on the binding mode of tolrestat (1), both inhibitors leave the specificity pocket in the closed state. Unexpectedly, the more potent ligand (2) extends the catalytic pocket by opening a novel subpocket. Access to this novel subpocket is mainly attributed to the rotation of an indole moiety of Trp 20 by about 35 degrees. The newly formed subpocket provides accommodation of the naphthyl portion of the ligand. The second inhibitor, 3, differs from 2 only by an extended glycolic ester functionality added to one of its carboxylic groups. However, despite this slight structural modification, the binding mode of 3 differs dramatically from that of the first inhibitor, but provokes less pronounced induced-fit adaptations of the binding cavity. Thus, a novel binding site conformation has been identified in a region where previous complex structures suggested only low adaptability of the binding pocket. Furthermore, the two ligand complexes represent an impressive example of how the slight change of a chemically extended side-chain at a given ligand scaffold can result in a dramatically altered binding mode. In addition, our study emphasizes the importance of crystal structure analysis for the translation of affinity data into structure-activity relationships. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:186 / 197
页数:12
相关论文
共 37 条
[1]   High-throughput crystallography for lead discovery in drug design [J].
Blundell, TL ;
Jhoti, H ;
Abell, C .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (01) :45-54
[2]   Biochemistry and molecular cell biology of diabetic complications [J].
Brownlee, M .
NATURE, 2001, 414 (6865) :813-820
[3]   Crystallography & NMR system:: A new software suite for macromolecular structure determination [J].
Brunger, AT ;
Adams, PD ;
Clore, GM ;
DeLano, WL ;
Gros, P ;
Grosse-Kunstleve, RW ;
Jiang, JS ;
Kuszewski, J ;
Nilges, M ;
Pannu, NS ;
Read, RJ ;
Rice, LM ;
Simonson, T ;
Warren, GL .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1998, 54 :905-921
[4]   Model of the catalytic mechanism of human aldose reductase based on quantum chemical calculations [J].
Cachau, R ;
Howard, E ;
Barth, P ;
Mitschler, A ;
Chevrier, B ;
Lamour, V ;
Joachimiak, A ;
Sanishvili, R ;
Van Zandt, M ;
Sibley, E ;
Moras, D ;
Podjarny, A .
JOURNAL DE PHYSIQUE IV, 2000, 10 (P10) :3-13
[5]   The structure of human aldose reductase bound to the inhibitor IDD384 [J].
Calderone, V ;
Chevrier, B ;
Van Zandt, M ;
Lamour, V ;
Howard, E ;
Poterszman, A ;
Barth, P ;
Mitschler, A ;
Lu, JH ;
Dvornik, DM ;
Klebe, G ;
Kraemer, O ;
Moorman, AR ;
Moras, D ;
Podjarny, A .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2000, 56 :536-540
[6]   Conformational flexibility in the peripheral site of Torpedo californica acetylcholinesterase revealed by the complex structure with a bifunctional inhibitor [J].
Colletier, JP ;
Sanson, B ;
Nachon, F ;
Gabellieri, E ;
Fattorusso, C ;
Campiani, G ;
Weik, M .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2006, 128 (14) :4526-4527
[7]   Naphtho[1,2-d]isothiazole acetic acid derivatives as a novel class of selective aldose reductase inhibitors [J].
Da Settimo, F ;
Primofiore, G ;
La Motta, C ;
Sartini, S ;
Taliani, S ;
Simorini, F ;
Marini, AM ;
Lavecchia, A ;
Novellino, E ;
Boldrini, E .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (22) :6897-6907
[8]   Application and limitations of X-ray crystallographic data in structure-based ligand and drug design [J].
Davis, AM ;
Teague, SJ ;
Kleywegt, GJ .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2003, 42 (24) :2718-2736
[9]   Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with fidarestat and minalrestat: Implications for the binding of cyclic imide inhibitors [J].
El-Kabbani, O ;
Darmanin, C ;
Schneider, TR ;
Hazemann, I ;
Ruiz, F ;
Oka, M ;
Joachimiak, A ;
Schulze-Briese, C ;
Tomizaki, T ;
Mitschler, A ;
Podjarny, A .
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2004, 55 (04) :805-813
[10]  
El-Kabbani O, 1999, MOL VIS, V5, pU1